▪ The safety of NeuroAiD is now well established. No difference has been shown between the 2 groups receiving either placebo or NeuroAiD in terms of adverse events. All clinical studies have reported NeuroAiD as a very safe product, without severe adverse event and rare and transitory nausea or vomiting in subjects with sensitive intestines.
▪ NeuroAiD has no impact on hepatic and renal functions or cardiovascular parameters, or other biological parameters1,2.
▪ NeuroAiD is not competing nor interacting with concomitant treatments. It is an add-on to usual poststroke preventive therapeutic strategy and can be added with other therapeutic products1,3.
▪ No increase in the rates of delayed adverse events have been reported up to 24 months after the initial treatment of NeuroAiD was discontinued 4,5.
1. Young S, et al. Safety profile of MLC601 (NeuroAiD) in acute ischemic stroke patients: A Singaporean substudy of the Chinese medicine NeuroAiD efficacy on stroke recovery study. Cerebrovascular Diseases 2010;30:1-6.
2. Gan R, et al. Danqi Piantan Jiaonang does not modify haemostasis, haematology, and biochemistry in normal subjects and stroke patients. Cerebrovascular Diseases 2008;25:450-456.
3. Chen C, et al. Chinese medicine NeuroAiD efficacy on stroke recovery: A double-blind, placebo-controlled, randomized study. Stroke 2013a;44:2093-2100
4. Venketasubramanian N, et al. CHInese medicine NeuroAiD efficacy on stroke recovery – Extension study (CHIMES-E): A multicenter study of long-term efficacy. Cerebrovascular Diseases 2015;39:309-318.
5. Shahripour RB, et al. A Randomized Trial to Assess the Long-Term Safety of NeuroAiD among Caucasian Patients with Acute Ischemic Stroke. Chin J Integr Med 2014;20(11): 812-817.